| Company Name | Novartis (Taiwan) Co., Ltd. |
|---|---|
| Protocol Number | CERL080ATW12 |
| Title of Study | Evaluating the Safety of Myfortic (Mycophenolate sodium) in patients with Lupus Nephritis: a 12 Month, Single-arm, Observational Study in Taiwan population |
| Primary Objective | To describe the safety profile of EC-MPS on LN patients |
| Number of Sites | 6 |
| Period of Study | From：16-Mar-2021 to：31-Mar-2024 |
| Number of Patients | 64人 |
| IRB Approval Date | 26-Nov-2020 |
| Publication Plan / Date | 31-Mar-2025 |
